HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)

More documents

Recommendations

Info

HYVET Trial: Study Design3845 patients > 80 years with continual hypertension and systolic blood pressure ≥160 mm Hg prior to randomizationProspective. Randomized. Double Blind. Placebo-Controlled. Mean follow-up 1.8yrsRActive Treatment1.5 mg Indapamide (SR)n=1933PlaceboMatching Dosen=19122 yrs. follow-upPrimary Endpoint: fatal and non-fatal strokesSecondary Endpoints: death from: stroke, cardiovascularcauses, cardiac causes and any causeCopyleft Clinical Trial Results. You Must Redistribute SlidesN Engl J Med 2008;358/ACC 2008
HYVET Trial: Baseline CharacteristicsCharacteristicActiveTreatment(n=1933)Placebo(n=1912)Age (years ± SD) 83.6 ± 3.2 83.5 ± 3.1Female (%) 1174 (60.7) 1152 (60.3)Blood Pressure (mm Hg)While sittingSystolicDiastolic173.0 ± 8.490.8 ± 8.5173.0 ± 8.690.8 ± 8.5While standingSystolicDiastolic168.0 ± 11.088.7 ± 9.3167.9 ± 11.188.6 ± 9.3Copyleft Clinical Trial Results. You Must Redistribute SlidesN Engl J Med 2008;358/ACC 2008
Page 1 and 2: HYVET TrialThe Hypertension in the
Page 3: HYVET Trial: Background• Blood pr
Page 7 and 8: HYVET Trial: Baseline Characteristi
Page 9 and 10: HYVET Trial: OutcomesMain Fatal and
Page 11: HYVET Trial: Summary• Lowering th

HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?